There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Early data with the RIPTAC HLD-0915 look competitive.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
